This study demonstrated that while ruxolitinib-mediated inhibition of ERK activation is observed in cell lines as well as in MPN patient and mouse model cells treated with ruxolitinib ex vivo, ERK remains activated in JAK2-V617F and MPL-W515L MPN model mice therapeutically treated with ruxolitinib. Here, JAK2 is linked to myeloproliferative neoplasm.